Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma ABFRA:7JK +2.10%58 3-1 Month Momentum % is 9.41% as of Sep. 20, 2026. GuruFocus rates FRA:7JK with a GF Score™ of 58/100. The stock has 6 warning signs investors should review. Among 1,018 Drug Manufacturers companies, EQL Pharma AB ranks better than 51.87% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-20), EQL Pharma AB's 3-1 Month Momentum % is 9.41%.
The industry rank for EQL Pharma AB's 3-1 Month Momentum % or its related term are showing as below:
FRA:7JK's 3-1 Month Momentum % is ranked better than 51.87% of 1018
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs FRA:7JK: 9.41
EQL Pharma AB (FRA:7JK) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
EQL Pharma AB 3-1 Month Momentum % Related Terms
FRA:7JK vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's 3-1 Month Momentum % falls into.
EQL Pharma AB (FRA:7JK) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (FRA:7JK) has a 3-1 Month Momentum % of 9.41% as of Sep. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on EQL Pharma AB and its competitors. According to the industry distribution chart, EQL Pharma AB ranks #490 out of 1018 companies in the Drug Manufacturers industry, placing it in the top 48.1%.
Is EQL Pharma AB's 3-1 Month Momentum % too high?
EQL Pharma AB's current 3-1 Month Momentum % is 9.41%. The Drug Manufacturers industry median 3-1 Month Momentum % is 2.33. EQL Pharma AB's value of 9.41% is 304.7% above this industry median. Based on the distribution chart, EQL Pharma AB ranks #490 out of 1018 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #490 out of 1018 companies for 3-1 Month Momentum %. This puts EQL Pharma AB in the upper half of its industry. The industry median 3-1 Month Momentum % is 2.33. EQL Pharma AB's value of 9.41% is 304.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.33, based on 1,018 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current 3-1 Month Momentum % of 9.41% is 304.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current 3-1 Month Momentum % is 9.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (FRA:7JK) has a current 3-1 Month Momentum % of 9.41%. The current 3-1 Month Momentum % is 9.41% and 304.7% above the Drug Manufacturers industry median of 2.33. EQL Pharma AB's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For EQL Pharma AB (FRA:7JK), the current 3-1 Month Momentum % is 9.41% as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
58GF Score
Get the complete analysis for FRA:7JK
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JK has been successfully added to your 
